As an example, the indication for the GC treatment in patients with RUCAM-based DIAIH was persistent or progressive serum ALT elevation despite withdrawal of the suspected causative drug or development of acute liver failure (AFL), with normalization of serum ALT activities after a median duration of 86 days [158]. This evidence concerns the gene GPT and acute liver failure.